Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin For Post Exposure Prophylaxis For COVID-19 Infection Among Close Contacts
NCT05231603Phase 3Terminated
- Sponsor
- Clinical Research Malaysia
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Treatment group: Ivermectin with Control group: Placebo (2 arms). Primary endpoint: Number of Covid-19 cases at 8 weeks. Started Feb 2022; status: terminated.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05231603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231603.